Shareholder Alert: Ademi LLP investigates whether NGM Biopharmaceuticals, Inc. has obtained a Fair Price in its transaction with Atlas Neon

MILWAUKEE, Feb. 26, 2024 /PRNewswire/ —  Ademi LLP is investigating NGM Bio (Nasdaq: NGM) for possible breaches of fiduciary duty and other violations of law in its transaction with Atlas Neon.

Click here to learn how to join the https://www.ademilaw.com/case/ngm-biopharmaceuticals-inc or call Guri Ademi toll-free at 866-264-3995.  There is no cost or obligation to you.

In the transaction, NGM Bio shareholders will receive only $1.55 in cash for each share they own.  The transaction agreement unreasonably limits competing transactions for NGM Bio by imposing a significant penalty if NGM Bio accepts a competing bid. NGM Bio insiders will receive substantial benefits as part of change of control arrangements.

We are investigating the conduct of NGM Bio’s board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.

If you own NGM Bio common stock and wish to obtain additional information, please contact Guri Ademi either at [email protected] or toll-free: 866-264-3995, or https://www.ademilaw.com/case/ngm-biopharmaceuticals-inc.                       

We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights throughout the country. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.

Contacts

Ademi LLP                                                                    
Guri Ademi
Toll Free: (866) 264-3995
Fax: (414) 482-8001

SOURCE Ademi LLP

Go to Source